Efficacy of belimumab in Primary Sjögren's syndrome: A systematic review

Reumatología Clínica - Tập 17 - Trang 170-174 - 2021
Noelia Álvarez-Rivas1, Hye Sang-Park2, Petra Díaz del Campo3, Mónica Fernández-Castro4, Hector Corominas2, José Luis Andreu5, Victoria Navarro-Compán6
1Rheumatology Department. Hospital Universitario San Agustín, Avilés, Spain
2Rheumatology Division, Hospital Universitari de la Santa Creu i Sant Pau, Barcelona, Spain
3Research Unit, Spanish Society of Rheumatology, Madrid, Spain
4Rheumatology Department. Hospital Universitario Infanta Sofia, Madrid, Spain
5Rheumatology Department, Hospital Universitario Puerta del Hierro Majadahonda, Majadahonda, Spain
6Rheumatology Department, IdiPaz, Hospital Universitario La Paz, Madrid, Spain

Tài liệu tham khảo

Rischmueller, 2016, Primary Sjögren's syndrome, Best Pract Res Clin Rheumatol, 30, 189, 10.1016/j.berh.2016.04.003 Qin, 2015, Epidemiology of primary Sjogren's syndrome: a systematic review and meta-analysis, Ann Rheum Dis, 74, 1983, 10.1136/annrheumdis-2014-205375 Kassan, 2004, Clinical manifestations and early diagnosis of Sjögren syndrome, Arch Intern Med, 164, 1275, 10.1001/archinte.164.12.1275 Brito-Zerón, 2017, Characterization and risk estimate of cancer in patients with primary Sjögren syndrome, J Hematol Oncol, 10, 90, 10.1186/s13045-017-0464-5 Schneider, 1999, BAFF, a novel ligand of the tumor necrosis factor family, stimulates B cell growth, J Exp Med, 189, 1747, 10.1084/jem.189.11.1747 Mariette, 2003, The level of BLyS (BAFF) correlates with the titre of autoantibodies in human Sjogren's syndrome, Ann Rheum Dis, 62, 168, 10.1136/ard.62.2.168 Ittah, 2006, B cell-activating factor of the tumor necrosis factor family (BAFF) is expressed under stimulation by interferon in salivary gland epithelial cells in primary Sjogren's syndrome, Arthritis Res Therapy, 8, R51, 10.1186/ar1912 Quartuccio, 2013, BLyS upregulation in Sjogren's syndrome associated with lymphoproliferative disorders, higher ESSDAI score and B-cell clonal expansion in the salivary glands, Rheumatology (Oxford, England), 52, 276, 10.1093/rheumatology/kes180 Navarra, 2011, Efficacy and safety of belimumab in patients with active systemic lupus erythematosus: a randomised, placebo-controlled, phase 3 trial, Lancet, 377, 721, 10.1016/S0140-6736(10)61354-2 Sackett, 1996, Evidence based medicine: what it is and what it isn’t, BMJ, 312, 71, 10.1136/bmj.312.7023.71 Liberati, 2009, The PRISMA statement for reporting systematic reviews and meta-analyses of studies that evaluate health care interventions: explanation and elaboration, PLoS Med., 6, e1000100, 10.1371/journal.pmed.1000100 Harbour, 2001, A new system for grading recommendations in evidence based guidelines, BMJ, 323, 334, 10.1136/bmj.323.7308.334 Mariette, 2015, Efficacy and safety of belimumab in primary Sjögren's syndrome: results of the BELISS open-label phase II study, Ann Rheum Dis, 74, 526, 10.1136/annrheumdis-2013-203991 De Vita, 2015, Efficacy and safety of belimumab given for 12 months in primary Sjögren's syndrome: the BELISS open-label phase II study, Rheumatology, 54, 2249 Quartuccio, 2016, Efficacy of belimumab and targeting of rheumatoid factor-positive B-cell expansion in Sjogren's syndrome: follow-up after the end of the phase II open-label BELISS study, Clin Exp Rheumatol, 34, 311 Souza, 2016, Rituximab effectiveness and safety for treating primary Sjogren's syndrome (pSS): systematic review and meta-analysis, PLOS ONE, 11, e0150749, 10.1371/journal.pone.0150749 Brito-Zeron, 2017, Characterization and risk estimate of cancer in patients with primary Sjogren syndrome, J Hematol Oncol, 10, 90, 10.1186/s13045-017-0464-5 Nocturne, 2016, Rheumatoid factor and disease activity are independent predictors of lymphoma in primary Sjogren's syndrome, Arthritis Rheumatol (Hoboken, NJ), 68, 977, 10.1002/art.39518 Fragkioudaki, 2016, Predicting the risk for lymphoma development in Sjogren syndrome: an easy tool for clinical use, Medicine, 95, e3766, 10.1097/MD.0000000000003766 Furie, 2018, Long-term safety and efficacy of belimumab in patients with systemic lupus erythematosus: a continuation of the Phase 3 United States BLISS-76 trial, Arthritis Rheumatol (Hoboken, NJ), 10.1002/art.40439